The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2023 | The value of circulating tumor cells for the staging of patients with NDMM
Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, discusses the value of using circulating tumor cells (CTCs) in the prognosis of patients with newly diagnosed multiple myeloma (NDMM), highlighting the benefits of this approach over standard bone marrow assessments. Dr Paiva further comments on the feasibility and high reproducibility of this approach. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
